newest glp-1 medications for type 2 diabetes 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with ADA 2025: Advances in Type
Pay in 4 interest-free payments of $7.34 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5









:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)


















